| The objective of this symposium is to help medical oncologists and other Health Care Professionals (HCPs) understand how to best utilize all three generations of EGFR-TKI directed therapies for NSCLC patients which now include four FDA-approved drugs: two 1st-generation drugs: erlotinib and gefitinib; one 2nd-generation drug: afatinib; and one 3rd-generation drug: osimertinib. In addition, two other 3rd-generation agents are in late-stage clinical development, including rociletinib, and BI 1482694 (formerly HM61713). The data to be presented at this symposium includes how to determine the differences among each of the many EGFR therapies based upon the latest EGFR mutation data such as EGFR exon 19 deletions, exon 21 L858R mutations, and the T790M-Positive and T790M-Negative mutations that are involved with Acquired Resistance to EGFR-directed therapy. The T790M mutation is the most common resistance mutation and is observed in approximately 60% of patients. This mutation occurs when the methionine is substituted for threonine at position 790 at exon 20, rendering 1st- and 2nd-generation EGFR-TKIs ineffective. Clinical trials with EGFR-directed therapies have underscored the importance of repeating biopsies with molecular analysis at the time of disease progression in patients with EGFR-mutated NSCLC. And with the availability of liquid biopsies, repeating biopsies will very well likely become more frequently done, resulting in improved patient outcomes. Other clinical data regarding EGFR TKI therapies will be addressed in this symposium. This will include monotherapy versus combination EGFR-based therapy, of which there is an increasing number of ongoing clinical trials, e.g., combining EGFR TKI therapy and immune therapy, and, combining EGFR TKI therapy with other targeted therapies, including other EGFR drugs; the key clinical trials which are ongoing and available for patient enrollment with EGFR TKIs; new information regarding the use of EGFR TKI therapy in Wild Type patients; the optimal sequencing of EGFR TKI therapies; the timing of when to switch EGFR TKI therapies; the differences in EGFR TKI toxicities and efficacy; and the pros and cons of using liquid versus tissue serial biopsies. | |
| CME and CE Credit
This symposium provides CME credit to physicians, CNE credit to nurses, CPE credit to pharmacists and a Certificate of Attendance for fellows, and all other HCPs. To receive CME/CE credit the learners have up to one week to complete the required symposium survey and answer four knowledge test questions found on the BioMedical Learning Institute (BMLI) Website. All of the PowerPoint slides, recorded audio and the presentations will be available approximately 6 weeks following the symposium. Bring your own "Smart Devices" to interact with the faculty
(iPhones, iPads, Tablets, Androids, etc.): This will enable participants to use their personal "smart devices" during the symposium to ask and answer all questions of the faculty. The educational need for this symposium is the result of continuing scientific advances involving an improved understanding of the mutations in the Epidermal Growth Factor Receptor (EGFR) in patients with Non-Small Cell Lung Cancer (NSCLC) causing resistance to EGFR-directed therapy, and an increasing number of FDA-approved EGFR-directed TKI therapies, and other EGFR TKIs in late-stage clinical development, and,an increasing number of possible improvements to patient outcome due to new, innovative EGFR-based combination therapies. | Gregory J. Riely, MD, PhD (Co-Chair)
Medical Oncologist, Thoracic Oncology Service
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
| Giorgio V. Scagliotti, MD, PhD (Co-Chair)
Head, Thoracic Oncology Unit
Department of Clinical and Biological Sciences
University of Turin
San Luigi Hospital
Orbassano, Italy
| Karen Kelly, MD
Associate Director for Clinical Research
Professor of Medicine
Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon,
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA
| Howard "Jack" West, MD
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education
Seattle, WA
| Heather A. Wakelee, MD
Assistant Professor
Department of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford Comprehensive Cancer Center
Stanford, CA
|
| PHYSICIAN - Compare and contrast the efficacy, safety, and mechanism of action differences between the first-, second- and third-generation EGFR-directed therapies for EGFR-positive NSCLC patients.
- Understand how to use liquid biopsies versus tissue biopsies to optimally sequence EGFR therapies to know when to switch therapies.
- Evaluate the pros and cons of using next generation sequencing (NGS) genomic testing panels and their ctDNA liquid biopsy tests.
- Analyze EGFR-Treatment-based strategies using monotherapy versus combination therapy for EGFR mutation-positive NSCLC.
NURSE AND PHARMACIST - Recall the efficacy, safety, and mechanism of action differences between the first-, second- and third-generation EGFR-directed therapies for EGFR-positive NSCLC patients.
- Review how to use liquid biopsies versus tissue biopsies to optimally sequence EGFR therapies to know when to switch therapies.
- List the pros and cons of using next generation sequencing (NGS) genomic testing panels and their ctDNA liquid biopsy tests.
- Identify EGFR-Treatment-based strategies using monotherapy versus combination therapy for EGFR mutation-positive NSCLC.
This live symposium on June 3, 2016 (including the live "real-time" Internet streaming simulcast} and archived enduring materials for one year) is designed to meet the educational needs of and help close Practice Gaps of medical oncologists, hematologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer, including physician assistants and fellows. Lung cancer is treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to this CME/CE activity for lung cancer patients with EGFR-Positive NSCLC. ACCREDITATION STATEMENTS AND CREDIT DESIGNATION  | The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The BioMedical Learning Institute designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|  | The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. UAN: 0838-0000-16-002-L01-P
Credits: 2 hours (0.2 ceus)
Type of Activity: Knowledge To receive CE contact hour credit attendance at the entire activity and the successful completion of the post-test and evaluation form is required.
|  | The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. The BioMedical Learning Institute designates this educational activity for 2 contact hours. Accreditation by the American Nurses Credentialing Center's COA refers to recognition of educational activities and does not imply approval or endorsement of any product. To receive CE contact hour credit attendance at the entire activity and the successful completion of the post-test and evaluation form is required.
| | Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 2 hours of Category 1 credits for attending this symposium. Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit. | Sheraton Grand Chicago Grand Ballroom
301 East North Water Street
Chicago, IL 60611
Phone: (312) 464-1000 AMERICANS WITH DISABILITIES ACT The Sheraton Grand Chicago represents that to the best of its knowledge its assembly areas, sleeping suites or rooms, public and common use areas and other covered portions of its facility and transportation services will be in compliance with the Americans with Disabilities Act. Please let us know if you have any special requirements. |
No comments:
Post a Comment